Anagrelide

Anagrelide capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms…

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: Anagrelide capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms…

What it is used for

Anagrelide capsules USP are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.

Side effects, and when to stop

The following adverse reactions are discussed in greater detail in other sections of the labeling:

Cardiovascular Toxicity
Bleeding Risk
Pulmonary Toxicity

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Anagrelide; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/anagrelide
APA 7th: sofidex. (2026, August 2). Anagrelide. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/anagrelide
AMA 11th: Anagrelide. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/anagrelide

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.